Human papillomavirus 11-valent recombinant vaccine - Chengdu Institute of Biological Products/National Vaccine and Serum Institute
Latest Information Update: 16 Jun 2022
At a glance
- Originator Chengdu Institute of Biological Products; National Vaccine & Serum Institute
- Class Cancer vaccines; Papillomavirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Human papillomavirus infections
- Phase II Cervical cancer
Most Recent Events
- 04 Jun 2022 Phase-III clinical trials in Human papillomavirus infections (Prevention, In adults) in China (IM) (NCT05262010)
- 08 Mar 2022 National Vaccine and Serum Institute in collaboration with Chengdu Institute of Biological Products plans a phase-III trial in Human papillomavirus infections (Prevention) in China (IM) (NCT05262010)
- 01 Mar 2022 National Vaccine and Serum Institute in collaboration with Chengdu Institute of Biological Products complete a phase II trial in Cervical cancer (Prevention, In adults) in China (IM) (NCT04436133)